| abstract |
The present disclosure relates to cytokines / chemokines, eg, IL-6, IL-8, IL, which correlate with improved clinical outcome, significantly increased survival time and significantly increased time to tumor or cancer recurrence Partially matured and activated dendritic cells that produce one or any combination of -12 and / or TNFα and / or all levels are provided. The determined threshold amounts of these cytokines are (i) an immunotherapy efficacy test for activated dendritic cells, (ii) selecting responder patients, (iii) rejecting non-responder patients, and ( iv) Can be used to screen for dendritic cell activation or maturation agents that can also induce the generation of a threshold amount of cytokine / chemokine. |